Neoadjuvant Chemotherapy in Pancreatic Cancer

Dear Colleagues,

Pancreatic cancer remains one of the most aggressive malignancies, with limited treatment options and poor overall survival rates. Neoadjuvant chemotherapy (NAC) has gained increasing attention as a strategy to improve surgical outcomes, enhance tumor resectability, and potentially increase long-term survival in patients with (borderline) resectable and locally advanced pancreatic cancer. However, careful patient selection is crucial to ensure that only those who will genuinely benefit from surgery proceed to resection, as not all patients respond favorably to NAC. Identifying reliable biomarkers and imaging criteria to predict response and optimize treatment decisions remains a key challenge.

This Special Issue explores the evolving role of NAC in pancreatic cancer, focusing on treatment protocols, including radiotherapy, clinical outcomes, resistance mechanisms, patient selection strategies, and emerging biomarkers. We invite original research, reviews, and clinical studies that provide new insights into optimizing NAC strategies and improving patient prognosis. Through this collection, we hope to advance understanding and contribute to the discussion on integrating NAC into standard pancreatic cancer treatment and selecting suitable surgical candidates after NAC.

Prof. Dr. Casper H. J. Van Eijck
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.